DesignMedix, Inc. has developed novel compounds by covalently linking a chemical moiety derived from a resistance reversal agent to a drug that has had strong resistance evolve against it, This can result in a new drug candidate that can fulfill the roles of both therapeutic agent and resistance reversal agent. Novel, patentable drug candidates can be created with the ability to reverse drug-resistance.

Malaria Cure

DesignMedix's most advanced drug candidate, DM1157, is in Phase I clinical trials. It was designed to provide a cure for drug-resistant malaria, and has been shown to overcome drug resistance in blood samples from over 200 patients infected with drug-resistant malaria parasites.